Login to Your Account



Regeneron Doubles Guidance for Eylea After Strong Launch

By Catherine Shaffer
Staff Writer

Tuesday, February 14, 2012

Regeneron revised its earnings guidance for Eylea (aflibercept) for 2012, from $140 million to $160 million to a range of $250 million to $300 million, after the newly launched therapy for wet age-related macular degeneration had a strong performance in its first quarter of sales. The Tarrytown, N.Y.-based firm reported that 30,000 injections of Eylea had been given to date.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription